Atopic Dermatitis

A recent study demonstrated the benefits and limitations of PatientsLikeMe for patients with atopic dermatitis and other skin conditions.

A dermatology expert reviews findings from a recently presented study on using other atopic dermatitis (AD) treatments within six months of initiating ruxolitinib cream. The expert assesses ruxolitinib's effectiveness and potential role in treatment, highlighting the need for further research on its long-term implications in AD management.

Bradley Burnam discusses results from an in-vivo model of atopic dermatitis.

Ensemble No.2, or ENS-002, is an investigational live biotherapeutic product first detected by Concerto Biosciences using its kChip technology.

Authorization for Eli Lilly's Ebglyss is based on positive results from the ADvocate 1, ADvocate 2, and ADhere studies.

Mickey Bryson recounts how Kristine Kucera, PA-C, MPAS, DHS, introduced a new medication and shared trial data with him, empowering him to make an informed decision about trying the new treatment.

James Del Rosso, DO, continues the discussion on managing acne in a female patient, emphasizing how to balance patient expectations and optimize skincare regimens, particularly when underlying conditions like polycystic ovarian syndrome are present.

An acne management expert discusses the importance of understanding patients' dietary choices on treatment outcomes, reviewing the different types of isotretinoin and highlighting the crucial role of micronized or food-independent formulations in effective acne care.

James Del Rosso, DO, presents the case of a 14-year old female suffering from mild to moderate acne and explores the role of isotretinoin, optimizing adolescent treatment protocols, and the rationale behind initial therapies such as oral antibiotics in similar cases.

The post-hoc analysis evaluated the relationship between lebrikizumab serum concentration levels and sustained clinical response after lebrikizumab discontinuation.

Lawrence Eichenfield, MD, explores the significant comorbidities and conditions, such as allergic rhinitis, anxiety, and asthma, that intersect with atopic dermatitis (AD), discussing their influence on disease management and treatment response, as well as the observed treatment patterns of patients with this condition before and after the initiation of ruxolitinib therapy.

Eli Lilly recently hosted a panel discussion with Olympic athlete Suni Lee to discuss the importance of finding a dermatologist who understands the burden of AD.

Kristine Kucera, PA-C, MPAS, DHS, and Mickey Bryson discuss Mickey's negative treatment outcomes and explore alternative options, such as switching to a psoriasis-specific medication, emphasizing the short-lived 2-week relief followed by symptom recurrence, which left Mickey resigned to the disease but still seeking a resolution.

A recent study found that AD not only affects mental health and QoL, but women’s sexual health and gestational desires as well.

An expert in the management of dermatological conditions shares insights on managing atopic dermatitis patients, discussing the real-world effectiveness and physician satisfaction with ruxolitinib cream as a treatment option, as well as its adoption among healthcare providers.

LEO Pharma's Adbry, a single-dose autoinjector, is expected to become available to patients in the coming months.

Researchers hypothesize that skin contact with e-cigarette fluids can trigger an inflammatory response.

Jonathan Silverberg, MD, PhD, MPH, and Melinda Gooderham, MSc, MD, FRCPC, debated which patients are a contender for systemic therapy.

The data, presented at RAVE 2024, continued a positive trend, building upon strong phase 1 results of rademikibart for patients with AD.

Gil Yosipovitch, MD, addresses the severity of chronic itch and sleep disturbances in patients with atopic dermatitis.

Kristine Kucera, PA-C, MPAS, DHS, discusses the atopic dermatitis patient experience alongside one of her patients, Mickey Bryson.

A study out of Japan found the burden on patients with atopic dermatitis and their caregivers can increase with age and disease severity.

The phase 3b/4 LEVEL-UP study assessed adolescents and adults with moderate to severe atopic dermatitis.

Roflumilast cream 0.15% is being evaluated for patients with mild to moderate atopic dermatitis down to 6 years.

Raj Chovatiya, MD, PhD, discusses how approved AD therapeutics currently address itch and whether any therapeutics will eventually have a remittive effect.

David Rosmarin, MD, shares key points from phase 3 data of ruxolitinib for vitiligo, as well as highlights the potential for targeting the STAT pathway in upcoming atopic dermatitis therapeutics.

Melinda Gooderham, MSc, MD, FRCPC, discusses potential new biologics for atopic dermatitis that target IL-22, IL-33, OX40, and more.

Robert Sidbury, MD, MPH, addresses the similarities and differences between the AAD’s recent atopic dermatitis guidelines and other guidelines from various groups and countries.

Kristine Kucera, PA-C, MPAS, DHS, discusses prescribing a PDE-4 inhibitor for Mickey Bryson's psoriasis and atopic dermatitis, emphasizing the absence of FDA-approved medications like JAK inhibitors, while Bryson underscores the challenges of daily injections, likening it to insulin use.

Amy Paller, MD, reviews the various types of therapeutics available and coming soon for pediatric atopic dermatitis and how she decides what treatment approach is best for each patient.